Lindbrook Capital’s Editas Medicine EDIT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-520
Closed -$2.43K 2850
2024
Q2
$2.43K Buy
+520
New +$2.93K ﹤0.01% 2285
2024
Q1
Sell
-227
Closed -$2.3K 2675
2023
Q4
$2.3K Buy
227
+89
+64% +$781 ﹤0.01% 2213
2023
Q3
$1.08K Sell
138
-2
-1% -$17 ﹤0.01% 2334
2023
Q2
$1.15K Sell
140
-35
-20% -$305 ﹤0.01% 2341
2023
Q1
$1.27K Sell
175
-71
-29% -$631 ﹤0.01% 2404
2022
Q4
$2.18K Buy
+246
New +$2.7K ﹤0.01% 2194
2022
Q3
Sell
-30
Closed -$467 2693
2022
Q2
$0 Sell
30
-108
-78% -$1.45K ﹤0.01% 2553
2022
Q1
$3K Sell
138
-329
-70% -$6.12K ﹤0.01% 1808
2021
Q4
$12K Buy
467
+437
+1,457% +$15K ﹤0.01% 1197
2021
Q3
$1K Hold
30
﹤0.01% 1699
2021
Q2
$2K Hold
30
﹤0.01% 1574
2021
Q1
$1K Hold
30
﹤0.01% 1699
2020
Q4
$2K Hold
30
﹤0.01% 1437
2020
Q3
$1K Hold
30
﹤0.01% 1537
2020
Q2
$1K Hold
30
﹤0.01% 1541
2020
Q1
$1K Hold
30
﹤0.01% 1434
2019
Q4
$1K Sell
30
-90
-75% -$2.25K ﹤0.01% 1372
2019
Q3
$3K Hold
120
﹤0.01% 1166
2019
Q2
$2K Hold
120
﹤0.01% 1218
2019
Q1
$2K Hold
120
﹤0.01% 1220
2018
Q4
$2K Buy
+120
New +$3.27K ﹤0.01% 1165

Other funds holding EDIT

Lindbrook Capital's EDIT Position: Q3 2024 in Review

Lindbrook Capital sold out of Editas Medicine (EDIT) in Q3 2024, closing a stake of 520 shares — an estimated $2.43K sold.

Lindbrook Capital first reported a position in EDIT in Q4 2018 and held it in 21 quarters. The position peaked at $12K in Q4 2021. 229 funds tracked by Wall St. Rank hold EDIT as of Q3 2024.

  • Lindbrook Capital reported no remaining Editas Medicine position as of Q3 2024 after selling out during the quarter.
  • Lindbrook Capital sold 520 Editas Medicine shares in Q3 2024, an estimated $2.43K.
  • Lindbrook Capital first reported a position in Editas Medicine in Q4 2018 and held it in 21 quarters.
  • Lindbrook Capital's Editas Medicine position peaked at $12K in Q4 2021.
  • 229 funds tracked by Wall St. Rank held Editas Medicine as of Q3 2024.

Based on Lindbrook Capital's 13F filing for Q3 2024, filed 1 Nov 2024.